Zobrazeno 1 - 10
of 205
pro vyhledávání: '"Hong-hong Yan"'
Autor:
Jia-Xin Lin, PhD, Kai Yin, PhD, Li-Xu Yan, PhD, Mei-Mei Zheng, PhD, Yang-Si Li, PhD, Shi-Ling Zhang, MS, Kang-Hui Zeng, MS, Hong-Hong Yan, MS, Hai-Yan Tu, PhD, Zhi-Hong Chen, MS, Xu-Chao Zhang, PhD, Qing Zhou, PhD, Jin-Ji Yang, PhD, Ben-Yuan Jiang, PhD, Qing-Ling Zhang, PhD, Yi-Long Wu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100704- (2024)
Introduction: Transformation to SCLC is a resistance mechanism to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma (LUAD). Nevertheless, the clinical and molecular features of SCLC transformation in LUAD with leptomeningeal metastases (L
Externí odkaz:
https://doaj.org/article/8dfa85064813427d9f719ff4ce66f49e
Autor:
Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab–chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical sta
Externí odkaz:
https://doaj.org/article/fac0f07d3dc04d809e388bf7352818af
Autor:
Jie Huang, Shi‐Ling Zhang, Chao Zhang, Weiye Huang, Zhenhua Zhang, Yu‐Qing Chen, Jun‐Wei Su, Hong‐Hong Yan, Hua‐Jun Chen, Jin‐Ji Yang, Junjian Wang, Yi‐Long Wu
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 5, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/49d76f8f4180466f917919a10b2c4b4c
Autor:
Jun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, Mei-Mei Fang, Xiao Xiao, Yi-Chen Zhang, Xu-Chao Zhang, Jian Su, Chong-Rui Xu, Hong-Hong Yan, Hua-Jun Chen, Yi-Long Wu, Jin-Ji Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Mesenchymal–epithelial transition ( MET ) amplification is a crucial oncogenic driver and a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) of non-small-cell lung cancer (NSCLC). Fluorescence i
Externí odkaz:
https://doaj.org/article/0ef134b3e84a4a9f9ebf044f8db4c295
Autor:
Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, Yingying Du, Jiu-Wei Cui, Qian Chu, Bing-Fei Xu, Ming-Ying Zheng, Jia-Yi Deng, Chang Lu, Xue-Wu Wei, Yang-Si Li, Mei-Mei Zheng, Ming-Yi Yang, Jie Huang, Anna Li, Xiao-Yan Bai, Yue-Li Sun, Chong-Rui Xu, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Hong-Hong Yan, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102238- (2023)
Summary: Background: Central nervous system (CNS) metastases is inevitable for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 is a novel EGFR-TKI with impressive CNS penetration. Methods: We initiated a pha
Externí odkaz:
https://doaj.org/article/76e8bbf8e79f4c32b3813a7376923f8f
Autor:
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer (NSCLC) (NCT01407822)
Externí odkaz:
https://doaj.org/article/1f184cb431924c6cb798d962d9892a83
Autor:
Hong‐xia Tian, Zhi‐hong Chen, Guang‐Ling Jie, Zhen Wang, Hong‐hong Yan, Si‐pei Wu, Shui‐lian Zhang, Dan‐xia Lu, Xu‐chao Zhang, Yi‐long Wu
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 396-406 (2023)
Abstract Objective NF1 is a tumor suppressor gene that encodes the neurofibromin protein and negatively regulates Ras signaling. This study was aimed to investigate the molecular, clinical characteristics, and prognostic features of NF1 gene in EGFR
Externí odkaz:
https://doaj.org/article/e5f7395017c04009a1b841fdf49f70cf
Autor:
Lingling Yang, Qing Zhou, Jian Su, Yi-Long Wu, Zhi-Hong Chen, Wen-zhao Zhong, Hong-Hong Yan, Qing Gou, Xue-Wu Wei, Xiao-Rong Yang, Jia-Yi Deng, Ming-Yi Yang, Jia-Qi Liu, Chong-Rui Xu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background The liver is a frequent site of metastases and liver metastases (LM) correlate with diminished immunotherapy efficacy in non-small cell lung cancer (NSCLC). This study aimed to analyze whether tumor response to immunotherapy differs betwee
Externí odkaz:
https://doaj.org/article/c3eaf6216ed14b64ba12a48c53dbf0e0
Autor:
Kai‐Cheng Peng, Jun‐Wei Su, Zhi Xie, Han‐Min Wang, Mei‐Mei Fang, Wen‐Feng Li, Yu‐Qing Chen, Xu‐Hui Guan, Jian Su, Hong‐Hong Yan, Xu‐Chao Zhang, Hai‐Yan Tu, Qing Zhou, Hua‐Jun Chen, Yi‐Long Wu, Jin‐Ji Yang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 11, Pp 1619-1630 (2022)
Abstract Background MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR
Externí odkaz:
https://doaj.org/article/82192f83a6d54e8a9200d4bcfce4e18f
Autor:
Zhen Wang, Xu-Chao Zhang, Wei-Neng Feng, Li Zhang, Xiao-Qing Liu, Wei-Bang Guo, Yan-Ming Deng, Qing-Feng Zou, Jin-Ji Yang, Qing Zhou, Bin-Chao Wang, Hua-Jun Chen, Hai-Yan Tu, Hong-Hong Yan, Yi-Long Wu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Circulating tumor cells (CTCs) are prognostic biomarker in non-small-cell lung cancer (NSCLC). CTCs could also be used as predictor of efficacy of systemic treatments in advanced NSCLC. Objectives: We described the dynamic changes of CTCs
Externí odkaz:
https://doaj.org/article/3d41e67e02a8435983d78956b0f52623